Literature DB >> 11241577

Methods for estimating the AIDS incubation time distribution when date of seroconversion is censored.

R B Geskus1.   

Abstract

In most cohort studies on HIV infection and AIDS, data on time from seroconversion to AIDS or death are doubly censored, both at the time origin and at the endpoint of interest. In epidemiological research, the most frequently adopted approach is to restrict the analysis to persons with narrow seroconversion intervals and to impute the midpoint of this interval as date of seroconversion. For many cohort studies, the consequence is that a substantial proportion of the data is not used. We consider four methods that are expected to be less biased when all cohort data are used: two imputation methods, conditional mean and multiple imputation, and two likelihood maximization methods. We derive the likelihood structure of the cohort data and clarify its dependence on study design. All methods are applied to data from the Amsterdam cohort study among injection drug users. In a simulation study the data generation process of this cohort study is imitated. The performance of midpoint, conditional mean and multiple imputation are compared. With midpoint imputation, both an analysis using the full data set, as well as one restricted to the cases with small seroconversion intervals, is performed. Conditional mean imputation comes out as the preferred method. It gives best results with respect to mean squared error. Moreover, when confidence intervals are computed through standard methods that ignore the uncertainty in the imputed date of seroconversion, coverage probabilities are almost correct. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11241577     DOI: 10.1002/sim.700

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Do HIV disease progression and HAART response vary among injecting drug users in Europe?

Authors:  Liselotte van Asten; Robert Zangerle; Ildefonso Hernández Aguado; Faroudy Boufassa; Barbara Broers; Raymond P Brettle; J Roy Robertson; Jim McMenamin; Roel A Coutinho; Maria Prins
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

2.  Imputation methods for doubly censored HIV data.

Authors:  Wei Zhang; Ying Zhang; Kathryn Chaloner; Jack T Stapleton
Journal:  J Stat Comput Simul       Date:  2009-10-01       Impact factor: 1.424

3.  Correcting for exposure misclassification using survival analysis with a time-varying exposure.

Authors:  Katherine Ahrens; Timothy L Lash; Carol Louik; Allen A Mitchell; Martha M Werler
Journal:  Ann Epidemiol       Date:  2012-10-05       Impact factor: 3.797

4.  HIV prevalence and incidence in rural Tanzania: results from 10 years of follow-up in an open-cohort study.

Authors:  Mwita Wambura; Mark Urassa; Raphael Isingo; Milalu Ndege; Milly Marston; Emma Slaymaker; Julius Mngara; John Changalucha; Ties J Boerma; Basia Zaba
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-15       Impact factor: 3.731

5.  Increasing risk behaviour can outweigh the benefits of antiretroviral drug treatment on the HIV incidence among men-having-sex-with-men in Amsterdam.

Authors:  Shan Mei; Rick Quax; David van de Vijver; Yifan Zhu; P M A Sloot
Journal:  BMC Infect Dis       Date:  2011-05-11       Impact factor: 3.090

6.  In vitro whole-genome analysis identifies a susceptibility locus for HIV-1.

Authors:  Corinne Loeuillet; Samuel Deutsch; Angela Ciuffi; Daniel Robyr; Patrick Taffé; Miguel Muñoz; Jacques S Beckmann; Stylianos E Antonarakis; Amalio Telenti
Journal:  PLoS Biol       Date:  2008-02       Impact factor: 8.029

7.  A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale.

Authors:  Cynthia Levy; Christopher L Bowlus; Elizabeth Carey; Julie M Crawford; Karen Deane; Marlyn J Mayo; W Ray Kim; Michael W Fried
Journal:  Hepatol Commun       Date:  2018-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.